Drugs Containing Excipient (Inactive Ingredient) 1,2-DIMYRISTOYL-SN-GLYCERO-3-CARBOXAMINOPROPYLPOLYETHYLENE GLYCOL 2000 METHYL ETHER

Branded drugs containing 1,2-DIMYRISTOYL-SN-GLYCERO-3-CARBOXAMINOPROPYLPOLYETHYLENE GLYCOL 2000 METHYL ETHER excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alnylam Pharmaceuticals Inc	ONPATTRO	patisiran	71336-1000	1,2-DIMYRISTOYL-SN-GLYCERO-3-CARBOXAMINOPROPYLPOLYETHYLENE GLYCOL 2000 METHYL ETHER	2029-04-15

Generic drugs containing 1,2-DIMYRISTOYL-SN-GLYCERO-3-CARBOXAMINOPROPYLPOLYETHYLENE GLYCOL 2000 METHYL ETHER excipient

Company	Ingredient	NDC	Excipient
Alnylam Pharmaceuticals Inc	patisiran	71336-1000	1,2-DIMYRISTOYL-SN-GLYCERO-3-CARBOXAMINOPROPYLPOLYETHYLENE GLYCOL 2000 METHYL ETHER

1,2-Dimyristoyl-sn-glycero-3-carboxyaminopropylpolyethylene glycol 2000 methyl ether Market Dynamics and Financial Trajectory

Last updated: August 26, 2026

The market for 1,2-dimyristoyl-sn-glycero-3-carboxyaminopropylpolyethylene glycol 2000 methyl ether, commonly called DMG-PEG 2000 or PEG2000-DMG, is a small, specialized segment of the pharmaceutical lipid and excipient market. Demand is tied to lipid nanoparticle manufacturing, especially mRNA vaccines and nucleic-acid medicines.

Revenue is not reported separately by pharmaceutical companies or excipient suppliers. The financial trajectory is therefore best assessed through downstream demand: COVID-19 vaccine volumes, the clinical pipeline for mRNA and RNA medicines, commercial lipid nanoparticle capacity, supplier qualification requirements, and patent-controlled formulation platforms.

The market experienced exceptional demand in 2020-2022, followed by a sharp COVID-19-related contraction. Its medium-term outlook depends on whether mRNA vaccines, personalized cancer vaccines, gene-editing products, and other RNA therapeutics generate recurring commercial demand. DMG-PEG 2000 remains strategically relevant, but its growth profile is likely to be lower and more concentrated than that of the overall lipid nanoparticle market.

What is DMG-PEG 2000 and how is it used?

DMG-PEG 2000 is a PEGylated phospholipid used to control lipid nanoparticle size, aggregation, circulation behavior, and storage stability. Its structure combines a dimyristoyl lipid anchor with a polyethylene glycol chain of approximately 2,000 molecular-weight units.

The excipient is used at low concentrations relative to the ionizable lipid, helper phospholipid, and cholesterol components of an LNP. That limits the absolute volume required per dose, but commercial mRNA products can still create substantial demand because manufacturing runs involve millions of doses and repeated batch production.

Core technical functions

Function	Commercial relevance
Surface PEGylation	Limits particle aggregation during formulation and storage
Particle-size control	Supports reproducible LNP manufacturing
Colloidal stabilization	Helps maintain dispersion quality
Reduced nonspecific interaction	Can improve formulation handling and in vivo behavior
Short lipid-anchor residence	May support release of the payload after administration

DMG-PEG 2000 is distinct from other PEG-lipids used in approved or investigational products. Pfizer-BioNTech's Comirnaty uses ALC-0159, a PEGylated lipid chemically different from DMG-PEG 2000. Moderna's Spikevax formulation uses PEG2000-DMG, making Moderna's product the clearest large-scale commercial demand driver for this specific excipient [1][2].

How large is the DMG-PEG 2000 market?

The standalone DMG-PEG 2000 market is not publicly quantified. Suppliers generally report product catalogs, not revenue by individual lipid. Pharmaceutical companies also include PEG-lipid costs within broader manufacturing expenses rather than disclosing the excipient cost per dose.

The addressable market can be divided into four layers:

1. Research-grade and preclinical sales.
2. GMP-grade supply for clinical trials.
3. Commercial supply for approved mRNA or RNA products.
4. Process-development, analytical, and formulation services.

The first two segments have many suppliers and relatively low barriers to entry. The third segment is smaller in supplier count but has higher qualification barriers, longer contracts, and stronger pricing power. The fourth segment benefits from continued LNP development even when vaccine sales decline.

A useful commercial distinction is between annual excipient consumption and excipient revenue. DMG-PEG 2000 is used at low formulation percentages, so volume growth may not translate into proportional revenue growth. GMP documentation, impurity control, batch consistency, analytical testing, and change-control commitments can account for a substantial portion of the selling price.

What drove the 2020-2022 demand spike?

The primary demand shock came from the rapid scale-up of LNP-enabled mRNA vaccines. Moderna's Spikevax and other mRNA vaccines required specialized lipids, including PEG-lipids, in large commercial manufacturing campaigns.

The demand cycle had three stages:

Period	Market condition	Effect on DMG-PEG 2000
2020	Emergency development and scale-up	Rapid qualification and capacity expansion
2021-2022	Mass vaccination and booster production	Exceptional commercial demand
2023 onward	Lower COVID vaccination volumes and inventory adjustment	Reduced demand and excess capacity

The decline in COVID vaccine revenue was material. Pfizer reported Comirnaty revenue of approximately $11.2 billion in 2023, down sharply from the prior year, and approximately $5.4 billion in 2024 [3][4]. Moderna reported 2024 product sales of approximately $3.1 billion, also reflecting the post-pandemic reduction in COVID vaccine demand [5].

These figures do not equal DMG-PEG 2000 revenue. They indicate the size of the downstream product base that historically generated demand for specialized LNP excipients.

What is the financial trajectory for DMG-PEG 2000?

The financial trajectory has four identifiable phases.

Phase one: pre-pandemic specialty excipient market

Before the COVID-19 vaccine market, DMG-PEG 2000 was primarily a research, formulation-development, and clinical-supply product. Sales were fragmented across academic laboratories, biotechnology companies, contract development and manufacturing organizations, and specialty lipid suppliers.

Pricing varied by purity, scale, documentation, and regulatory grade. Small research quantities commanded high unit prices, while kilogram-scale commercial supply had lower unit pricing but much greater contract value.

Phase two: pandemic acceleration

The pandemic converted PEG-lipids from laboratory inputs into strategically important commercial raw materials. Suppliers had to support:

• Larger production campaigns.
• GMP manufacturing.
• Multi-site quality systems.
• Traceable raw materials.
• Validated analytical methods.
• Regulatory change control.
• Continuity of supply during global logistics constraints.

The main financial benefit accrued to suppliers with established lipid chemistry, GMP infrastructure, and direct relationships with vaccine manufacturers or CDMOs.

Phase three: post-pandemic correction

The correction began as governments and healthcare systems reduced COVID vaccine procurement. Lower booster uptake, product inventory, and more selective vaccination recommendations reduced commercial LNP manufacturing volumes.

DMG-PEG 2000 suppliers faced a mixed environment:

• Lower demand from COVID vaccine programs.
• Continued clinical demand for non-COVID mRNA programs.
• Greater price competition in research-grade products.
• Stronger qualification barriers in GMP-grade products.
• Greater customer concentration around a limited number of LNP developers.

Phase four: platform diversification

The next growth phase depends on applications beyond COVID vaccines. The most commercially relevant areas are:

• Seasonal influenza mRNA vaccines.
• Combination respiratory vaccines.
• Personalized cancer vaccines.
• Protein-replacement mRNA products.
• In vivo gene-editing systems.
• siRNA and antisense delivery systems.
• Rare-disease nucleic-acid medicines.
• Self-amplifying RNA products.

Not all of these applications will use DMG-PEG 2000. Developers may choose alternative PEG-lipids to optimize biodistribution, tolerability, payload release, repeat dosing, or tissue targeting.

Which companies supply DMG-PEG 2000?

The supplier landscape includes specialized lipid manufacturers, catalog reagent companies, and CDMOs. Public catalogs have included products from companies such as Avanti Polar Lipids, Cayman Chemical, BroadPharm, Merck/Sigma-Aldrich channels, and other specialty lipid suppliers. Availability, grade, batch size, and regulatory documentation differ materially by supplier.

Supplier tiers

Supplier tier	Typical customer	Main buying criteria
Research-grade catalog suppliers	Universities and early-stage biotechnology companies	Purity, availability, small quantities
GMP specialty lipid suppliers	Clinical-stage developers and CDMOs	GMP systems, analytical package, reproducibility
Strategic commercial suppliers	Approved-product manufacturers	Capacity, dual sourcing, change control, regulatory support
Custom manufacturers	Developers with proprietary lipid requirements	Process ownership, confidentiality, scale-up capability

The most valuable supplier position is not necessarily the lowest-cost source. It is qualified supply that can support regulatory submissions and commercial production without unplanned changes to particle size, encapsulation efficiency, potency, or stability.

What FDA regulatory status applies to DMG-PEG 2000?

DMG-PEG 2000 is an excipient used within drug products and is not an independently approved active pharmaceutical ingredient. FDA regulatory status depends on the finished product, formulation, route of administration, manufacturing process, and submitted safety data.

FDA and excipient considerations

The key regulatory questions are:

• Whether the exact lipid is identified in the finished-product application.
• Whether the excipient has prior human exposure at the proposed route and dose.
• Whether the sponsor has adequate toxicology and immunogenicity data.
• Whether residual solvents, oxidized species, hydrolysis products, and PEG-related impurities are controlled.
• Whether the supplier and manufacturing site are covered by the regulatory filing.
• Whether a supplier or process change requires comparability data.

DMG-PEG 2000 does not have a conventional FDA Orange Book listing because the Orange Book lists approved drug products and patent information, not standalone excipient catalog entries [6]. Patent protection generally attaches to the finished LNP composition, therapeutic use, manufacturing process, or delivery method.

What patents protect DMG-PEG 2000 and LNP formulations?

Patent exposure is usually indirect. A company purchasing DMG-PEG 2000 does not obtain freedom to operate for a particular LNP product merely by acquiring the excipient.

Relevant patent categories include:

Composition patents

These cover combinations of:

• Ionizable lipid.
• PEG-lipid.
• Cholesterol.
• Helper phospholipid.
• Nucleic-acid payload.
• Particle-size or molar-ratio ranges.

A patent may cover DMG-PEG 2000 expressly or cover a genus broad enough to include it.

Method-of-use patents

These cover delivery of mRNA, siRNA, gene-editing components, vaccines, or other nucleic acids using LNPs. Claims can focus on disease treatment, dosing schedules, tissue targeting, or repeat administration.

Manufacturing patents

These can cover microfluidic mixing, solvent exchange, encapsulation conditions, purification, filtration, and fill-finish processes.

Platform patents

Companies including Moderna, BioNTech, Arbutus Biopharma, Acuitas Therapeutics, Alnylam Pharmaceuticals, and other LNP developers have developed patent portfolios around lipid chemistry and nucleic-acid delivery. Some disputes have involved broad LNP technology rather than infringement by the excipient itself.

The commercial implication is that patent risk is assessed at the product and process level. DMG-PEG 2000 is a component of the risk analysis, not usually the entire legal issue.

When does DMG-PEG 2000 lose exclusivity?

DMG-PEG 2000 has no single market-wide exclusivity expiration date. Exclusivity depends on separate patents covering the chemical compound, manufacturing process, LNP composition, therapeutic use, and commercial product.

Chemical compound patents may expire independently of formulation patents. A formulation patent can remain relevant after the underlying excipient chemistry is available from multiple suppliers. Regulatory exclusivity also attaches to a finished medicine, not to the excipient.

For commercial planning, the more relevant questions are:

• Whether the selected LNP formulation is covered by active patents.
• Whether the supplier has enforceable process or composition rights.
• Whether a generic or biosimilar framework applies to the finished product.
• Whether a competitor can use a different PEG-lipid or non-PEG formulation.
• Whether the product sponsor has settlement or license obligations.

Which companies are challenging LNP patent estates?

Patent challenges have focused primarily on LNP platforms, ionizable lipids, and mRNA delivery rather than on standalone DMG-PEG 2000. Arbutus Biopharma and Genevant Sciences have pursued litigation involving LNP intellectual property against companies commercializing mRNA vaccines, including Moderna and Pfizer/BioNTech-related products. Moderna has also faced patent disputes involving mRNA vaccine technology and LNP delivery [7][8].

These disputes create two types of exposure:

1. Product-level exposure for the manufacturer.
2. Supply-chain exposure if a formulation must be redesigned or a royalty-bearing license is required.

The existence of litigation does not establish infringement or damages. Final outcomes depend on claim construction, validity, ownership, licensing rights, and appellate review.

What generic entry risks exist for DMG-PEG 2000-based products?

Generic entry is less predictable than in conventional small-molecule markets. A competitor may need to demonstrate similarity in:

• Lipid composition.
• Particle-size distribution.
• Encapsulation efficiency.
• Payload integrity.
• Release profile.
• Potency.
• Stability.
• Immunogenicity and safety.

For an mRNA product, a competitor may also face manufacturing patents and method-of-use patents. A different PEG-lipid could avoid one patent but create new development and regulatory requirements.

Generic launch scenarios

Scenario	Market effect
Same LNP composition with no enforceable blocking patent	Rapid price pressure after approval
Alternative PEG-lipid formulation	Longer development cycle and comparability burden
New ionizable-lipid platform	Potentially stronger differentiation but higher R&D cost
Patent settlement with delayed entry	Incumbent retains near-term revenue
Biosimilar-style competition	Limited direct applicability because mRNA vaccines are not biologics in the conventional protein sense

The highest generic-entry risk applies to mature, high-volume products with stable demand and well-characterized formulations. The risk is lower where the product depends on complex manufacturing, rapidly changing strains, personalized payloads, or a broad platform patent estate.

How does DMG-PEG 2000 compare with alternative PEG-lipids?

DMG-PEG 2000 competes with PEG-lipids that differ in anchor chemistry, PEG chain length, hydrolysis rate, and particle-retention characteristics.

PEG-lipid type	Typical strategic use	Key trade-off
DMG-PEG 2000	LNP stabilization and relatively transient surface protection	Limited persistence may affect circulation and repeat-dose design
DSPE-PEG 2000	More persistent PEG-lipid anchoring	Greater retention can affect payload release and repeat dosing
ALC-0159-type PEG lipid	Commercial mRNA vaccine formulation	Product-specific platform and patent position
Other biodegradable PEG-lipids	Next-generation LNP designs	Development and regulatory comparability burden
Non-PEG surface systems	Avoidance of PEG-related immune concerns	May create new stability and biodistribution challenges

Alternative PEG-lipids are a competitive constraint because they reduce dependence on any single excipient. They also create switching costs. Changing the PEG-lipid can alter particle formation, potency, biodistribution, storage stability, and safety.

What is the manufacturing and intellectual-property barrier?

Manufacturing barriers are higher than the chemical synthesis alone suggests. Commercial-grade supply requires control of lipid purity, PEG molecular-weight distribution, residual solvents, water content, oxidation, hydrolysis, endotoxins, bioburden, and batch-to-batch consistency.

The main barriers are:

• Reproducible synthesis at scale.
• Control of regioisomer and degradation profiles.
• Reliable PEGylation chemistry.
• Validated purification.
• Analytical reference standards.
• GMP documentation.
• Regulatory support for supplier changes.
• Capacity reservation during demand surges.

Intellectual property can protect the synthesis route, purification method, lipid structure, formulation ratio, or therapeutic use. Trade secrets may be more important than patents for process parameters and quality-control methods.

What licensing deals affect the DMG-PEG 2000 market?

Licensing is concentrated at the LNP-platform and finished-product levels. Publicly disclosed arrangements have involved:

• Moderna and Arbutus-related LNP technology disputes and licenses.
• BioNTech and Genevant-related technology arrangements.
• Acuitas Therapeutics and LNP technology used in mRNA vaccine development.
• University and biotechnology licenses covering ionizable lipids, delivery systems, and manufacturing methods.

These agreements can include upfront payments, milestones, royalties, field restrictions, and sublicensing rights. They generally do not create a standalone royalty on every kilogram of DMG-PEG 2000 sold. The financial impact appears through product economics and freedom-to-operate costs.

What is the revenue exposure for DMG-PEG 2000 suppliers?

Supplier revenue exposure is concentrated in a small number of large customers and programs. COVID vaccine demand created unusually high exposure to a few manufacturers. Post-pandemic demand is more diversified by development program but remains concentrated by commercial volume.

Revenue drivers include:

• Number of commercial LNP products.
• Dose volumes.
• PEG-lipid concentration per dose.
• Batch yield and process losses.
• GMP grade versus research grade.
• Contract duration.
• Dual-source requirements.
• Customer inventory policy.
• Success rate of clinical programs.

A supplier with low catalog sales but a qualified commercial contract may have greater strategic value than a supplier with high research-grade unit sales. Conversely, a supplier dependent on a single vaccine program faces high volume volatility.

What is the five-year market outlook?

The base case is a smaller post-pandemic market with gradual growth from non-COVID RNA medicines. Commercial demand should remain below the 2021-2022 peak unless multiple mRNA or LNP-based products achieve broad adoption.

Scenario analysis

Scenario	Operating assumptions	Effect on DMG-PEG 2000
Downside	COVID demand continues to decline; few non-COVID approvals	Lower volumes, price compression, excess capacity
Base case	Selective mRNA vaccine demand and several clinical-to-commercial transitions	Stable specialty market with moderate growth
Upside	Cancer vaccines, gene editing, influenza, and rare-disease products scale	Stronger GMP demand and capacity expansion

The highest-value opportunity is not commodity excipient volume. It is qualified, regulatory-ready supply for products that use LNPs at commercial scale. Suppliers that can support alternate sourcing, process validation, and global regulatory filings are positioned better than catalog-only vendors.

Key Takeaways

• DMG-PEG 2000 is a specialized PEG-lipid excipient used in LNP drug delivery.
• Moderna's Spikevax is a major commercial product associated with PEG2000-DMG demand.
• Pfizer's Comirnaty uses a different PEGylated lipid, ALC-0159.
• The market surged during the COVID-19 vaccine scale-up and contracted after 2022.
• Standalone DMG-PEG 2000 revenue is not publicly disclosed.
• Future growth depends on non-COVID mRNA vaccines, cancer vaccines, gene editing, and other RNA medicines.
• FDA status applies through the finished drug product rather than an independent Orange Book listing for the excipient.
• Patent risk is concentrated in LNP compositions, therapeutic uses, manufacturing methods, and delivery platforms.
• GMP qualification, analytical control, and regulatory change management are more important commercial barriers than basic chemical availability.
• The base-case outlook is stabilization and selective growth, not a return to pandemic-era demand.

FAQs

Is DMG-PEG 2000 the same as ALC-0159?

No. Both are PEGylated lipids used in LNP formulations, but their chemical structures are different. ALC-0159 is associated with Comirnaty, while PEG2000-DMG is associated with Moderna's Spikevax formulation.

Can DMG-PEG 2000 be purchased as a GMP pharmaceutical excipient?

Yes. Specialty suppliers offer research-grade and, in some cases, GMP or GMP-compatible material. The regulatory value depends on the supplier's quality system, documentation, manufacturing controls, and acceptance by the finished-product sponsor.

Does DMG-PEG 2000 itself have an Orange Book patent listing?

No standalone Orange Book listing applies to the excipient. Orange Book patent information is associated with approved drug products and relevant listed patents.

Are biosimilars likely to replace DMG-PEG 2000-based mRNA products?

The conventional biosimilar framework is not the primary competition model for mRNA vaccines. Competition is more likely to arise through alternative LNP formulations, new ionizable lipids, different PEG-lipids, or competing nucleic-acid delivery systems.

What factor most affects the price of commercial DMG-PEG 2000?

GMP qualification and supply assurance generally affect commercial value more than the nominal chemical synthesis cost. Batch consistency, impurity control, documentation, capacity reservation, and regulatory change management determine whether a supplier can support an approved product.

References

1. Moderna, Inc. (2024). 2024 annual report. U.S. Securities and Exchange Commission.

2. U.S. Food and Drug Administration. (2023). Spikevax prescribing information. FDA.

3. Pfizer Inc. (2024). 2023 annual report. U.S. Securities and Exchange Commission.

4. Pfizer Inc. (2025). 2024 annual report. U.S. Securities and Exchange Commission.

5. Moderna, Inc. (2025). 2024 annual report. U.S. Securities and Exchange Commission.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

7. Arbutus Biopharma Corporation. (2024). Annual report. U.S. Securities and Exchange Commission.

8. Genevant Sciences Ltd. v. Moderna, Inc., patent litigation records, U.S. District Court for the District of Delaware.